Summary of Zhejiang Jingxin Pharmaceutical Co., Ltd.'s 2025 Annual Report Stock code: 002020 Stock abbreviation: Jingxin Pharmaceutical Announcement number: 2026016 Zhejiang Jingxin Pharmaceutical Co., Ltd Summary of the 2025 Annual Report
- Important reminders The summary of this annual report is from the full text of the annual report, in order to fully understand the company's operating results, financial situation and future development plans Investors should go to the media designated by the China Securities Regulatory Commission to carefully read the full text of the annual report.
| In addition to the following directors, other directors attended the deliberations in person | | Board meetings of this report | | | | --- | --- | --- | --- | --- | --- | --- | | Names of directors who did not attend in person | | Failure to attend directorship in person | | Reasons for not attending the meeting in person | Name of the entrusted person | | | | Wang Neng Neng | Director | | Business trip | | Hong Yunfei | | | Lei Ying | Independent Director | | Business trip | | Xu Pan |
Non-standard audit opinion reminders □ Applicable Not applicable The profit distribution plan for the reporting period or the plan for the conversion of provident fund into share capital deliberated by the board of directors Applicable □ Not applicable Whether to use provident fund to increase share capital
| □ Yes | No | |||||||
|---|---|---|---|---|---|---|---|---|
| The profit distribution plan approved by the board of directors of the company is as follows: to stop | 2025 | Year | 12 | On March 31, the total share capital of the company | ||||
| 861,029,140 | Shares deduct | 40,147,895 | Behind the stock | 820,881,245 | shares are the base, and all shareholders are each | |||
| 10 | Dividend Dividend | 3.5 yuan (tax included | .) ), 0 bonus shares (tax included | ). ), and do not use the provident fund to increase the share capital |
The profit distribution plan for preferred shares for the reporting period approved by the board of directors □ Applicable Not applicable 1
Summary of Zhejiang Jingxin Pharmaceutical Co., Ltd.'s 2025 Annual Report 2. Basic information of the company
- Company Profile Stock abbreviation Jingxin Pharmaceutical Stock code 002020 Stock Listed Exchange Shenzhen Stock Exchange Contacts and contact details Secretary of the Board of Directors Securities Representative Name Hong Yunfei Shi Xiaomeng Office Address Gangcheng Avenue, Xiaoshan District, Hangzhou City, Zhejiang Province No. 1831-25 Fax 0571- 85221587 Phone 0571 － 86575888 Email stock@jingxinpharm.com
- Introduction to the main business or products in the reporting period
(1) Main business Zhejiang Jingxin Pharmaceutical Co., Ltd. is a national key high-tech enterprise, which has obtained national/EU (Germany) GMP, ISO14001, and the United States FDA on-site certification and self-operated import and export rights, mainly engaged in the research and development of chemical preparations, traditional Chinese medicine, biological preparations, chemical APIs, and medical devices Production, production and sales. During the reporting period, the company's product structure continued to be optimized, and the profitability of its main business grew steadily. The main product types are as follows: Product category Product field Main product name Product use Rosuvastatin calcium tablets/dispersible tablets, simvastatin tablets, pitavastatin calcium dispersible tablets, atorvata Cardiovascular and cerebrovascular drugs are mainly used for hypertension, hyperlipidemia and coronary heart disease Calcium tablets, aspirin enteric-coated tablets, benzene sulfonic acid Amlodipine tablets, irbesartan tablets, etc